FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Luciana Yamamoto de AlmeidaFernanda Dos Santos MoreiraGuilherme Augusto Silva Dos SantosFlorence Juana Maria Cuadra ZelayaCésar Alexander OrtizMichelle AgostiniFlávia Sammartino MarianoDébora Campanella BastosUlisses Ribaldo Nicolau DaherLuiz Paulo KowalskiRicardo Della ColettaEdgard GranerPublished in: Oral diseases (2021)
Our results suggest that orlistat enhances the chemosensitivity of SCC-9 LN-1 cells to cisplatin and paclitaxel by downregulating cyclin B1.